These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 23677206)
1. A victory for global public health in the Indian Supreme Court. 't Hoen E J Public Health Policy; 2013 Aug; 34(3):370-4. PubMed ID: 23677206 [TBL] [Abstract][Full Text] [Related]
2. "To patent or not to patent? the case of Novartis' cancer drug Glivec in India". Gabble R; Kohler JC Global Health; 2014 Jan; 10():3. PubMed ID: 24393270 [TBL] [Abstract][Full Text] [Related]
3. India's patent case victory rattles Big Pharma. Chatterjee P Lancet; 2013 Apr; 381(9874):1263. PubMed ID: 23589911 [No Abstract] [Full Text] [Related]
4. Indian Supreme Court rejects Novartis's appeal on drug patent. Arie S BMJ; 2013 Apr; 346():f2099. PubMed ID: 23550079 [No Abstract] [Full Text] [Related]
5. Patent watch: Indian Supreme Court blocks Novartis’ Glivec patent. Harrison C Nat Rev Drug Discov; 2013 May; 12(5):336-7. PubMed ID: 23598506 [No Abstract] [Full Text] [Related]
6. Supreme Court of India rejects Novartis’ cancer drug patent. Heseltine P Pharm Pat Anal; 2013 May; 2(3):299-300. PubMed ID: 24237056 [No Abstract] [Full Text] [Related]
7. [The Glivec® case: the first example of a global debate on the drug patent system]. Moital I; Bosch F; Farré M; Maddaleno M; Baños JE Gac Sanit; 2014; 28(6):470-4. PubMed ID: 25110309 [TBL] [Abstract][Full Text] [Related]
8. India's decision on Gleevec: implications for the future. Wilensky GR Healthc Financ Manage; 2013 May; 67(5):32-3. PubMed ID: 23678685 [No Abstract] [Full Text] [Related]
9. How can the public health community help to invigorate a 'health first' perspective in global drug development debates? Freeman P; Robbins A J Public Health Policy; 2013 Aug; 34(3):361-9. PubMed ID: 23803714 [No Abstract] [Full Text] [Related]
10. Big Pharma vs India’s Patent Office. Pharm Pat Anal; 2012 Nov; 1(5):529. PubMed ID: 24236921 [No Abstract] [Full Text] [Related]
11. Engineered in India--patent law 2.0. Kapczynski A N Engl J Med; 2013 Aug; 369(6):497-9. PubMed ID: 23862973 [No Abstract] [Full Text] [Related]
12. Taking TRIPS to India--Novartis, patent law, and access to medicines. Mueller JM N Engl J Med; 2007 Feb; 356(6):541-3. PubMed ID: 17287473 [No Abstract] [Full Text] [Related]
13. The Indian Supreme Court's judgment in the case of Glivec(®) - the uncertain future of pharmaceutical patents in India. Thikkavarapu PR Pharm Pat Anal; 2014 Mar; 3(2):117-9. PubMed ID: 24588585 [No Abstract] [Full Text] [Related]
14. India's rejection of Novartis's patent is but a small step in the right direction. Bhaumik S BMJ; 2013 Apr; 346():f2412. PubMed ID: 23596223 [No Abstract] [Full Text] [Related]
15. Drugmakers struggle with Indian patents. Cancer Discov; 2012 Dec; 2(12):OF5. PubMed ID: 23230206 [TBL] [Abstract][Full Text] [Related]
16. Is India ready to lead the battle for fair access to medicines? Lancet Oncology Lancet Oncol; 2013 May; 14(6):437. PubMed ID: 23639313 [No Abstract] [Full Text] [Related]
17. MSF challenges Novartis's action over Indian patent for imatinib. Mudur G BMJ; 2007 Jan; 334(7586):172. PubMed ID: 17255582 [No Abstract] [Full Text] [Related]
18. Will the refusal of patent protection for Glivec® discourage future pharmaceutical innovation in India? Albutt J Pharm Pat Anal; 2013 Jul; 2(4):439-41. PubMed ID: 24237119 [No Abstract] [Full Text] [Related]
19. A modest but meaningful decision for Indian drug patents. Attaran A Lancet; 2014 Aug; 384(9942):477-9. PubMed ID: 24976117 [No Abstract] [Full Text] [Related]
20. India: Court upholds patent law denying patents for slightly modified versions of existing drugs. Swamy M HIV AIDS Policy Law Rev; 2007 Dec; 12(2-3):50-1. PubMed ID: 18459215 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]